Nucleic acid biomarker and use thereof

• Main Authors: Beckman Robert Allen, Freeman Daniel J, Blum Sabine, Jin Xiaoping, Mendell-Harary Renee Jeanne, Schneider Matthias
• Format: Patent
• Language: Chinese; English
• Published: 10.08.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low. 本发明针对鉴别和治疗具有肿瘤和其它疾病的人受试者的方法，其包括评估所述人受试者的mRNA水平上的HRG基因的表达以及向mRNA水平上的HRG基因的表达被评估为高的人受试者施用包括抗-HER3抗体的治疗。本发明还针对鉴别具有肿瘤和其它疾病的人受试者的方法，其包括评估所述人受试者的mRNA水平上的HRG基因的表达以及对mRNA水平上的HRG基因的表达被评估为低的人受试者停止包括抗-HER3抗体的治疗。